HK1076822A1 - Fusion protein of hiv regulatory/accessory proteins hiv - Google Patents

Fusion protein of hiv regulatory/accessory proteins hiv

Info

Publication number
HK1076822A1
HK1076822A1 HK05108707A HK05108707A HK1076822A1 HK 1076822 A1 HK1076822 A1 HK 1076822A1 HK 05108707 A HK05108707 A HK 05108707A HK 05108707 A HK05108707 A HK 05108707A HK 1076822 A1 HK1076822 A1 HK 1076822A1
Authority
HK
Hong Kong
Prior art keywords
hiv
proteins
fusion protein
nucleic acids
regulatory
Prior art date
Application number
HK05108707A
Other languages
English (en)
Inventor
Paul Howley
Sonja Leyrer
Eva Felder
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of HK1076822A1 publication Critical patent/HK1076822A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK05108707A 2002-05-16 2005-09-30 Fusion protein of hiv regulatory/accessory proteins hiv HK1076822A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200754 2002-05-16
PCT/EP2003/005039 WO2003097675A1 (fr) 2002-05-16 2003-05-14 Proteine hybride des proteines regulateurs de vih/accessoires

Publications (1)

Publication Number Publication Date
HK1076822A1 true HK1076822A1 (en) 2006-01-27

Family

ID=29433046

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108707A HK1076822A1 (en) 2002-05-16 2005-09-30 Fusion protein of hiv regulatory/accessory proteins hiv

Country Status (24)

Country Link
US (7) US20050222388A1 (fr)
EP (2) EP1652857B9 (fr)
JP (3) JP2006502704A (fr)
KR (4) KR101196178B1 (fr)
CN (3) CN101108882A (fr)
AT (2) ATE407143T1 (fr)
AU (2) AU2003240638B2 (fr)
BR (1) BR0309963A (fr)
CA (1) CA2483640A1 (fr)
CY (1) CY1108638T1 (fr)
DE (2) DE60323407D1 (fr)
DK (2) DK1652857T3 (fr)
EA (1) EA007154B1 (fr)
ES (2) ES2253675T3 (fr)
HK (1) HK1076822A1 (fr)
IL (3) IL164178A0 (fr)
MX (1) MXPA04010683A (fr)
NO (1) NO20045229L (fr)
NZ (2) NZ536499A (fr)
PL (2) PL372092A1 (fr)
PT (1) PT1652857E (fr)
SI (2) SI1506223T1 (fr)
UA (3) UA85373C2 (fr)
WO (1) WO2003097675A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101196178B1 (ko) * 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
CA2519025A1 (fr) 2003-03-28 2004-10-07 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Produits de recombinaison hiv-1 multiclade immunogenes et multivalents, et methodes d'utilisation de ceux-ci
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
EP2044224A4 (fr) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Particules de type virus chimérique
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2313496T3 (en) 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
AU2009285547B2 (en) 2008-08-28 2012-05-31 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US20120135032A1 (en) 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
US9358281B2 (en) * 2009-10-09 2016-06-07 New York University Methods, agents and peptides for inducing an innate immune response in HIV vaccination
JP5917402B2 (ja) 2009-11-03 2016-05-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
CA2879667C (fr) 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Reconstitution et auto-reconstitution ameliorees du compartiment hematopoietique comprenant un polypeptide myc
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015192339A1 (fr) * 2014-06-18 2015-12-23 中山大学 Vecteur chimère et son procédé de préparation et son utilisation
CN104130331B (zh) * 2014-06-19 2017-06-06 中山大学 一种抗hiv‑1病毒药物及其制备和应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN105330729A (zh) * 2015-11-18 2016-02-17 南京医科大学 一种人类免疫缺陷病毒Vpr蛋白的制备方法
EP3548425B1 (fr) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Formulations de nanoparticules
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11666651B2 (en) 2019-11-14 2023-06-06 Aelix Therapeutics, S.L. Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942747A1 (fr) * 1996-08-26 1999-09-22 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FI105105B (fi) 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CZ20022643A3 (cs) 2000-01-31 2003-02-12 Smithkline Beecham Biologicals S. A. Farmaceutický prostředek
AU1194802A (en) * 2000-03-02 2001-12-11 Univ Emory DNA expression vectors and methods of use
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
ES2307640T3 (es) * 2000-07-14 2008-12-01 The Trustees Of The University Of Pennsylvania Vacunad de adn codificantes de proteinas accesorias del vih.
CA2427257C (fr) * 2000-11-01 2014-01-21 The Government Of The United States Of America Vecteurs d'expression permettant de provoquer une reponse immunitaire et procedes d'utilisation desdits vecteurs
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
KR101196178B1 (ko) * 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질

Also Published As

Publication number Publication date
CY1108638T1 (el) 2014-04-09
EP1506223A1 (fr) 2005-02-16
US8143054B2 (en) 2012-03-27
NZ556144A (en) 2008-04-30
US20050222388A1 (en) 2005-10-06
MXPA04010683A (es) 2005-02-17
KR20050010000A (ko) 2005-01-26
AU2003240638B2 (en) 2008-05-15
KR20110099058A (ko) 2011-09-05
CN101108882A (zh) 2008-01-23
DK1652857T3 (da) 2009-01-05
EP1652857A3 (fr) 2007-03-14
JP2009178165A (ja) 2009-08-13
AU2008252074B2 (en) 2012-02-16
US8389275B2 (en) 2013-03-05
CN1982332A (zh) 2007-06-20
IL164178A (en) 2011-01-31
ATE310016T1 (de) 2005-12-15
US20060257974A1 (en) 2006-11-16
US8147839B2 (en) 2012-04-03
DE60302356T2 (de) 2006-08-03
ES2253675T3 (es) 2006-06-01
DE60323407D1 (de) 2008-10-16
NO20045229L (no) 2004-11-29
AU2008252074A1 (en) 2009-01-08
ATE407143T1 (de) 2008-09-15
US20090280561A1 (en) 2009-11-12
ES2313166T3 (es) 2009-03-01
SI1652857T1 (sl) 2009-02-28
UA82998C2 (ru) 2008-06-10
PL397252A1 (pl) 2012-04-10
DE60302356D1 (de) 2005-12-22
EA007154B1 (ru) 2006-08-25
US20120142096A1 (en) 2012-06-07
BR0309963A (pt) 2005-02-22
DK1506223T3 (da) 2006-04-10
AU2003240638A1 (en) 2003-12-02
CN1653085A (zh) 2005-08-10
PL372092A1 (en) 2005-07-11
JP2006502704A (ja) 2006-01-26
KR20120106894A (ko) 2012-09-26
PT1652857E (pt) 2008-12-12
CA2483640A1 (fr) 2003-11-27
IL197304A0 (en) 2011-07-31
EP1652857A2 (fr) 2006-05-03
US7569228B2 (en) 2009-08-04
KR100996330B1 (ko) 2010-11-23
NZ536499A (en) 2008-04-30
IL164178A0 (en) 2005-12-18
KR20100063126A (ko) 2010-06-10
US20100047871A1 (en) 2010-02-25
WO2003097675A1 (fr) 2003-11-27
EP1652857B1 (fr) 2008-09-03
CN1325512C (zh) 2007-07-11
EP1652857B9 (fr) 2009-10-14
KR101196178B1 (ko) 2012-11-01
SI1506223T1 (sl) 2006-04-30
US20100047268A1 (en) 2010-02-25
EP1506223B1 (fr) 2005-11-16
US20120142097A1 (en) 2012-06-07
US8137931B2 (en) 2012-03-20
EA200401504A1 (ru) 2005-04-28
US8435535B2 (en) 2013-05-07
UA85373C2 (ru) 2009-01-26
UA92788C2 (ru) 2010-12-10
JP2010099084A (ja) 2010-05-06

Similar Documents

Publication Publication Date Title
IL197304A0 (en) Fusion protein of hiv regulatory/accessory proteins
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
HUP0303753A2 (hu) Fúziós fehérjék immunogenitásának csökkentése
DK1645631T3 (da) Neisseria antigener og præparater
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
WO2003029285A3 (fr) Identification de nouveaux epitopes cd8 des proteines du vih-1 presentant des proprietes therapeutiques et vaccinales contre les infection par le vih
GB2336844A (en) Anti-hiv peptides and proteins
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
WO2005047483A3 (fr) Renta: un immunogene du vih, et utilisations de renta
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
WO1994029472A3 (fr) Mengovirus utilise comme vecteur d'expression de polypeptides etrangers
WO2002068464A3 (fr) Proteine hybride utilisee pour bloquer la proteine nef du vih

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140514